 BOSTON, May 04, 2021 GLOBE NEWSWIRE -- Galecto, Inc. NASDAQ: GLTO, a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the period ended March 31, 2021 and provided a corporate update. 